The most dominantly enriched gene in PDOs from oxaliplatin-resistant tumors was ZNF300 (log2 fold change 21, FDR <0.001, Figure 4B), which has previously been associated with platinum resistance in lung cancer cells.45 The gene discussed is ZNF300; the disease is lung carcinoma.